At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 53 enrolled
Drug / intervention
Ociperlimab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Ociperlimab, Tislelizumab, and 1 other intervention for Relapsed Diffuse Large B-cell Lymphoma and Refractory Diffuse Large B-cell Lymphoma. Completed, enrolled 53 participants across 19 sites.
Detailed Summary
The primary purpose of this study is to assess the safety and tolerability of ociperlimab (BGB-A1217) in combination with tislelizumab (BGB-A317) or rituximab in participants with relapsed or refractory (R/R) diffuse large B cell lymphoma (DLBCL)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartApr 2022
Primary CompletionAug 2024
TodayJul 2026
First PostedMar 4, 2022
Enrollment StartApr 25, 2022
Primary CompletionAug 30, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.3 years ago
Interventions
Ociperlimabdrug
administered intravenously
Tislelizumabdrug
Administered intravenously once every 3 weeks
Rituximabdrug
Administered intravenously once every 3 weeks